文献速递贫血与红细胞疾病白血病MDS 与骨髓增殖性肿瘤

ERCC6L2 疾病的临床全貌:从骨髓衰竭到急性白血病

The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia.
PubMed 文献 · Blood · 2023-01-01

该回顾性系列纳入来自全球11个中心的52例(35个家系)携带双等位基因胚系ERCC6L2变异者,随访1165人年。基线时32例诊断为骨髓衰竭、15例为血液系统恶性肿瘤;中位18岁(范围2-65岁)。血液系统恶性肿瘤中位发病年龄37.0岁(95%CI 31.5-42.5),骨髓衰竭与血液系统恶性肿瘤患者3年总生存率分别为95%(95%CI 85-100)和19%(95%CI 0-39)。

要点

  • 双等位基因胚系ERCC6L2变异者中,基线32例为骨髓衰竭、15例为血液系统恶性肿瘤。
  • 血液系统恶性肿瘤中位发病年龄37.0岁(95%CI 31.5-42.5;范围12-65岁)。
  • 骨髓衰竭患者3年总生存率95%(95%CI 85-100),血液系统恶性肿瘤患者19%(95%CI 0-39)。

核心结论

  • 结果证明早期识别和积极监测对携带双等位基因胚系ERCC6L2变异的患者很重要。

研究设计与样本

  • 回顾性收集来自全球11个中心的52例(35个家系)携带双等位基因胚系ERCC6L2变异者,随访1165人年。
  • 基线中位年龄18岁(范围2-65岁)。

主要发现

  • 基线时32例诊断为骨髓衰竭,15例诊断为血液系统恶性肿瘤。
  • 检出19种不同ERCC6L2变异,并在芬兰患者中发现奠基者突变c.1424delT。
  • 尽管骨髓严重发育低下且存在体细胞TP53突变,全血细胞计数变化轻微,有无血液系统恶性肿瘤者之间无显著差异。
  • 疾病进展征象包括TP53变异等位基因频率升高、巨核细胞和/或红系发育异常以及骨髓形态中红系优势。
  • 血液系统恶性肿瘤中位发病年龄37.0岁(95%CI 31.5-42.5;范围12-65岁)。

关键数值与推荐

  • 骨髓衰竭患者3年总生存率95%(95%CI 85-100)。
  • 血液系统恶性肿瘤患者3年总生存率19%(95%CI 0-39)。
  • 伴TP53突变的骨髓增生异常综合征或急性髓系白血病接受造血干细胞移植者结局差,3年总生存率28%(95%CI 0-61)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biallelic germ line excision repair cross-complementing 6 like 2 (ERCC6L2) variants strongly predispose to bone marrow failure (BMF) and myeloid malignancies, characterized by somatic TP53-mutated clones and erythroid predominance. We present a series of 52 subjects (35 families) with ERCC6L2 biallelic germ line variants collected retrospectively from 11 centers globally, with a follow-up of 1165 person-years. At initial investigations, 32 individuals were diagnosed with BMF and 15 with a hematological malignancy (HM). The subjects presented with 19 different variants of ERCC6L2, and we identified a founder mutation, c.1424delT, in Finnish patients. The median age of the subjects at baseline was 18 years (range, 2-65 years). Changes in the complete blood count were mild despite severe bone marrow (BM) hypoplasia and somatic TP53 mutations, with no significant difference between subjects with or without HMs. Signs of progressive disease included increasing TP53 variant allele frequency, dysplasia in megakaryocytes and/or erythroid lineage, and erythroid predominance in the BM morphology. The median age at the onset of HM was 37.0 years (95% CI, 31.5-42.5; range, 12-65 years). The overall survival (OS) at 3 years was 95% (95% CI, 85-100) and 19% (95% CI, 0-39) for patients with BMF and HM, respectively. Patients with myelodysplastic syndrome or acute myeloid leukemia with mutated TP53 undergoing hematopoietic stem cell transplantation had a poor outcome with a 3-year OS of 28% (95% CI, 0-61). Our results demonstrated the importance of early recognition and active surveillance in patients with biallelic germ line ERCC6L2 variants.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hakkarainen M, Kaaja I, Douglas SPM, et al. The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia. Blood. 2023. PMID: 36952636. doi:10.1182/blood.2022019425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。